Sugi Predict

Sugi Predict / Compounds / SCHEMBL1541487

SCHEMBL1541487

SCHEMBL1541487

NS(=O)(=O)c1ccc(NCC2CCCCC2)c([N+](=O)[O-])c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.64
▸ HTT P42858 3/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ PKM P14618 4/20 0.57
▸ POLB P06746 2/20 0.57
▸ NPSR1 Q6W5P4 3/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ XBP1 P17861 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ GAA P10253 3/20 0.54
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ DOT1L Q8TEK3 1/20 0.48
▸ WNK1 Q9H4A3 1/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16037790 0.90 KMT2A (0.56) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL16037789 0.90 KMT2A (0.56) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL16038200 0.90 KMT2A (0.56) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL29387647 0.89 MAPT (0.59) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL1956216 0.89 MAPT (0.56) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL523815 0.89 MAPT (0.59) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL1956219 0.89 MAPT (0.56) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL1700685 0.88 MAPT (0.55) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL1957756 0.88 MAPT (0.55) MAPTHTTSMN1; SMN2ALDH1A1PKM
SCHEMBL1700680 0.88 MAPT (0.55) MAPTHTTSMN1; SMN2ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109776414-B Bcl-2 protein inhibitor and preparation method and application thereof 山东大学 2022-04-22 — — CN disclosed
EP-3666758-A1 PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE AbbVie Inc. (US) 2020-06-17 — — EP disclosed
CN-106008322-B sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2018-09-04 — — CN disclosed
CN-106008322-A BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2016-10-12 — — CN disclosed
EP-2507229-B1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBVIE INC (US) 2016-10-05 — — EP disclosed
EP-3048098-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AbbVie Bahamas Limited (BS) 2016-07-27 — — EP disclosed
CN-102307872-B BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2016-06-15 — — CN disclosed
EP-2376480-B1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBVIE INC (US) 2016-06-01 — — EP disclosed
US-9315488-B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE INC. (US) 2016-04-19 — — US disclosed
EP-1685119-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBVIE BAHAMAS LTD (BS) 2016-03-09 — — EP disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-20050159427-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2005-07-21 — — US disclosed
WO-2005049593-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed
WO-2005049594-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885HTT 3524/4885SMN1; SMN2 1440/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885HTT 3398/4885SMN1; SMN2 1656/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885HTT 3524/4885SMN1; SMN2 1440/4885
US-20050159427-A1 N-acylsulfonamide apoptosis promoters BAX, API5, CCAR2 MAPT 4640/4885HTT 2482/4885SMN1; SMN2 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.